ECCO 2024 Highlights Podcast

In this episode [12.57], Medicom’s correspondent covers 6 presentations from the 19th Congress of the European Crohn’s and Colitis Organisation (ECCO 2024), held in Stockholm, Sweden, from 21-24 February 2024.

The topics discussed are:

1. PROFILE: Top-down treatment strategy benefits patients with early CD
   A top-down treatment strategy resulted in improved outcomes compared with an accelerated step-down treatment strategy in patients with newly diagnosed Crohn’s disease (CD), without increasing the risk of serious infections.
2. VIVID-1: Mirikizumab meets expectations in CD
   Mirikizumab met its primary endpoints in a phase 3 trial, testing this agent among patients with moderate to severe Crohn’s disease (CD). The response rates were comparable between patients who had failed on a prior biologic therapy and those who had not.
3. Extended mesenterectomy or mesenteric-sparing surgery in CD?
   Extended mesenterectomy did not outperform mesenteric-sparing surgery in patients with Crohn’s disease (CD) undergoing primary ileocolic resection, data of an international trial displayed. Therefore, the authors advise to perform mesenteric-sparing surgery in these patients.
4. Tofacitinib as rescue option for acute severe UC
   Tofacitinib appeared to be an effective treatment for steroid-refractory patients with acute severe ulcerative colitis (UC), displaying a swift onset of action and a high clinical response rate in bio-naïve and bio-experienced patients in the TRIUMPH trial. The authors suggest that tofacitinib could be a treatment option for hospitalised patients with severe UC.
5. Promising data for JAK inhibitors in CD
   Both ritlecitinib and brepocitinib were associated with improved efficacy outcomes compared with placebo in patients with moderate to severe Crohn’s disease (CD). The agents were generally safe and well tolerated.
6. Clear case for NUDT15 genetic testing in Asian IBD patients
   A study into the clinical utility of NUDT15 pharmacogenetic testing showed that NUDT15 variant carriage was associated with an increased risk of thiopurine-induced myelosuppression and severe myelosuppression. The authors concluded that there is a clear case for NUDT15 testing among East and South Asian patients with inflammatory bowel disease (IBD).

Enjoy listening!

Copyright ©2024 Medicom Medical Publishers



Posted on 11 March, 202412 March, 2024